Temsirolimus
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Temsirolimus |
| DrugBank ID | DB06287 |
| Brand Names (EU) | Torisel |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.54% |
Approved Indication (EMA)
Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | liposarcoma | 99.54% | DL |
| 2 | ovarian myxoid liposarcoma | 99.47% | DL |
| 3 | clear cell renal carcinoma | 99.39% | DL |
| 4 | vulva sarcoma | 99.09% | DL |
| 5 | uterine corpus myxoid leiomyosarcoma | 98.88% | DL |
| 6 | anus leiomyosarcoma | 98.77% | DL |
| 7 | uterine corpus epithelioid leiomyosarcoma | 98.76% | DL |
| 8 | small intestinal sarcoma | 98.64% | DL |
| 9 | retroperitoneal sarcoma | 98.60% | DL |
| 10 | leiomyosarcoma | 98.60% | DL |
| 11 | renal cell carcinoma associated with neuroblastoma | 98.53% | DL |
| 12 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | 98.53% | DL |
| 13 | unclassified renal cell carcinoma | 98.53% | DL |
| 14 | childhood kidney cell carcinoma | 98.09% | DL |
| 15 | spindle cell liposarcoma | 97.66% | DL |
| 16 | mixed endometrial stromal and smooth muscle tumor | 97.24% | DL |
| 17 | dermatofibrosarcoma protuberans | 97.23% | DL |
| 18 | angiolipoma | 96.72% | DL |
| 19 | childhood malignant neoplasm | 96.57% | DL |
| 20 | familial rhabdoid tumor | 96.55% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.